Alnylam Pharmaceuticals Inc (ALNY)

[mlkrborn]

ALNY news ; $9.50 1:01PM Alnylam Pharma and Regulus Therapeutics report Nature article implicates microRNAs in the pathogenesis of obesity and Type 2 Diabetes (ALNY) 9.58 -0.09 : The cos announced the publication in Nature of new pre-clinical data in mice about the antagonism of microRNA-103 and microRNA-107 (miR-103/107). Data from a collaborative study performed by Regulus, Alnylam and ETH Zurich demonstrated that antagonism of miR-103/107 with proprietary chemically modified anti-miR oligonucleotides could promote insulin signaling in both liver and adipose tissue. Silencing miR-103/107 in animal models of obesity improved glucose homeostasis, suggesting that these microRNAs are potential targets for the treatment of diabetes.